Format

Send to

Choose Destination
Cell. 2019 Feb 21;176(5):1240-1240.e1. doi: 10.1016/j.cell.2019.01.051.

SnapShot: Cancer Immunotherapy with Oncolytic Viruses.

Author information

1
Departments of Pathology, Biology, and Microbiology & Immunolgy, Faculty of Medicine, Dalhousie University, Halifax, NS, Canada.
2
Departments of Medicine & Biochemistry and Microbiology & Immunology, University of Ottawa, ON, Canada; Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.

Abstract

Oncolytic viruses (OVs) preferentially infect and kill cancer cells without harming normal cells. OVs can revert cancer-associated immune suppression and initiate clinically meaningful antitumor immune responses. OVs and their resultant immunological events can act at both primary and metastatic sites. Thus, OVs can be exploited for cancer gene therapies and immunotherapies alone or in combination with other interventions, including immune checkpoint blockade.

PMID:
30794777
DOI:
10.1016/j.cell.2019.01.051

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center